This series features essays by Dr. Kenneth Serbin, Professor of History, originally posted on his blog, At Risk for Huntington's Disease."
Huntington's Disease (HD) is a genetically caused brain disorder that causes uncontrollable bodily movements and robs people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.
Blog Posts from 2025
Brain donation programs now perhaps at risk of losing funding are key to a Huntington's disease cure a family's story, Kenneth P. Serbin PhD
With ‘great promise’ for treating Huntington’s disease, four drug programs press ahead (Part II), Kenneth P. Serbin PhD
A Foundation's Role in Collaboratively Enabling Drug Discovery, Robert A. Pacifici PhD
With ‘great promise’ for treating Huntington’s disease, four drug programs press ahead (Part I), Kenneth P. Serbin PhD
More optimistic than ever, CHDI head scientist sees unprecedented mobilization in the fight to treat Huntington’s disease, Kenneth P. Serbin PhD
As a ‘biological being,’ I embrace science’s fight against disease, Kenneth P. Serbin PhD
Savoring 20 years of my Huntington’s disease blog, Kenneth P. Serbin PhD
Blog Posts from 2024
At Harvard MGH’s Mouro Pinto Lab, deploying CRISPR in the quest to cure Huntington’s disease, Kenneth P. Serbin PhD
At HDF symposium, a Huntington’s disease ‘hero’ who prays for scientists to find a cure, Kenneth P. Serbin PhD
Exploring the unique qualities of INGREZZA, the newest FDA-approved drug for Huntington’s disease chorea, Kenneth P. Serbin PhD
Aiming for multiple targets for Huntington’s disease therapies a hopeful report from the Yang lab at UCLA, Kenneth P. Serbin PhD
‘Striving for a cure’ highlights from the 19th Annual Huntington’s Disease Therapeutics Conference, Kenneth P. Serbin PhD
Huntington’s disease community will 'get there' in search for therapies, CHDI chief scientist declares after ‘terrific’ conference, Kenneth P. Serbin PhD
At CHDI conference, advocates inspire acceleration of quest for Huntington’s disease therapies, Kenneth P. Serbin PhD
Scientists interacting with Huntington’s disease patients in the quest for therapies, Kenneth P. Serbin PhD
Blog Posts from 2023
New book by longtime advocate describes Milton Wexler’s incomparable contributions to Huntington’s disease research and beyond, Kenneth P. Serbin PhD
Adding to arsenal of movement disorder drugs approved by FDA, Neurocrine pledges to seek anxiously awaited therapies to slow progression of Huntington’s disease, Kenneth P. Serbin PhD
Lessons from the Maui wildfires for human solidarity and the fight against Huntington’s and other diseases, Kenneth P. Serbin PhD
After another critical Huntington’s disease clinical trial proves negative, a time to embrace self-care and caregiving, Kenneth P. Serbin PhD
Blog Posts from 2022
#FightDiseaseNotWar, Kenneth P. Serbin PhD
In ‘Journal of Huntington’s Disease,’ my article analyzes record of my ‘realistic and unapologetic’ blog, Kenneth P. Serbin PhD
Ten years out of the terrible and lonely Huntington’s disease closet, as new research and investments offer hope for treatments, Kenneth P. Serbin PhD
After abrupt shutdown of Triplet Therapeutics, Huntington’s disease community regroups in the fight for therapies, Kenneth P. Serbin PhD
Roche confirms second, more focused, trial of Huntington’s disease drug will start early next year, Kenneth P. Serbin PhD
After other firms’ setbacks, Prilenia readies for readout on Huntington’s drug that improves daily function, Kenneth P. Serbin PhD